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Dear Professor Cornblath, 
Systemic amyloidosis is a disorder of protein folding in which there is extracellular 
deposition of insoluble fibrillar proteins (Falk et al., 1997). At least 30 proteins are known to 
form amyloid deposits in vivo in humans and classification is based on the identity of the 
respective amyloid fibril precursor protein (Sipe et al., 2012). Transthyretin-associated 
amyloidosis (ATTR) is the commonest cause of hereditary amyloidosis, with more than 100 
mutations in TTR that increase its amyloid-forming potential. Peripheral and autonomic 
neuropathy and cardiomyopathy are hallmarks of the disease but broad clinical 
heterogeneity is recognised (Plante-Bordeneuve and Said, 2011). Wild-type TTR is 
amyloidogenic in the very elderly with histological evidence of amyloid deposition in up to 
25% of autopsied patients greater than 80 years old (Lie and Hammond., 1998). A restrictive 
cardiomyopathy is the best characterised manifestation with preceding carpal tunnel 
syndrome (CTS) in 48.9%; the role of joint and ligament amyloid deposition in the 
pathogenesis of a variety of orthopaedic disorders in increasing (Pinney et al., 2013).  
 
Lumbar spinal stenosis is typically presents in late middle age (Katz and Harris, 2008). It is 
characterised by compression of sensory and motor nerves to the lower limbs, exacerbated 
by exercise and relieved with rest; disability due to pain, impaired mobility and sphincter 
disturbance accrues with time (Suri et al., 2010). It is most often multifactorial; related to 
disc degeneration, spondylolisthesis and age-related degenerative processes affecting 
connective tissue. Amyloid deposits have been found in the ligamentum flavum of 25/26 
lumbar canal stenosis cases, with co-localised immunohistochemical staining for 
transthyretin in 5/15 specimens studied (Westmark et al., 2014). In a larger orthopaedic 
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cohort of 111 patients congo-red staining identified amyloid deposits in 42.6% with 
confirmation TTR-derived amyloid by Western blot or mass spectrometry in the majority of 
these: 39/44 (Sueyoshi et al., 2011). No definite cases of spinal stenosis due to mutant TTR 
have been described. Currently, surgical decompression is the mainstay of treatment with 
clinical improvement in most cases (Sasaji et al., 2011) but with recent developments in the 
treatment of systemic amyloidoses, particularly transthyretin-derived amyloidosis (Adams 
et la., 2016}), should we be paying more attention to the underlying pathogenesis of this 
common condition? 
Here we describe a patient with genetically confirmed ATTR, a family history of the disease 
and histological confirmation following carpal tunnel release surgery but no other 
manifestations. Finding ATTR deposits contributing to lumbar spinal stenosis had significant 
treatment implications. 
A woman of German ancestry was found to be a carrier of a heterozygous I84S TTR 
mutation at the age of 42. Genetic testing was performed on the basis of a strong family 
history of systemic amyloidosis affecting her mother, maternal uncle and older brother with 
carpal tunnel syndrome, peripheral neuropathy and restrictive cardiomyopathy. From this 
point she was under co-ordinated 2 yearly reviews by the National Amyloidosis Centre 
(NAC) in the Royal Free Hospital and peripheral nerve and autonomic services in the 
National Hospital of Neurology and Neurosurgery. At age 44, tissue confirmation was made 
on flexor retinaculum from carpal tunnel release surgery. She had been suffering from 
bilateral worsening CTS for approximately 10 years but denied symptoms of peripheral 
neuropathy, autonomic dysfunction, cardiac failure or visual impairment. Systemic and 
neurological examinations were normal except for positive Tinnel’s at the left wrist. Nerve 
conduction studies (NCS) were normal other than evidence of bilateral CTS and borderline 
TTR-spinal stenosis 
 
sural sensory nerve action potentials (8µV on the right). Normal thermal thresholds suggest 
lack of marked small fibre dysfunction. Autonomic screening tests and 24 hour BP 
monitoring were normal. ECOG performance status was 1, echocardiogram was normal but 
DPD scintigraphy (Perugini grade 1) and cardiac MRI were in keeping with early cardiac 
amyloidosis, NT pro-BNP=16 pMol/L. She was commenced on Diflunisal 500mg. There was 
no evidence of disease progression either subjectively or objectively over the next 4 years. 
 
At age 47, she developed a patch of numbness on the dorsum of her left foot and pain in her 
lower back which radiated to both anterior thighs and knees. Initially this came on after 
walking approximately one mile and would worsen if she continued walking but settle 
completely after 10-15 minutes rest. Over the next 12 months the sensory disturbance in 
her foot progressed proximally along the L5 dermatome, pain worsened in severity and 
exercise tolerance declined to less than 100 yards. She also described a tingling sensation in 
the same distribution and occasional feelings of her “legs giving way”. She had long-standing 
urge incontinence of urine but latterly developed a constant leak with urinary and fecal 
incontinence and worsening of all symptoms on bending and straining. There were no upper 
limb complaints or symptoms above the neck. Neurological examination now revealed 
decreased, but not absent, pinprick sensation from the left great toe and dorsum of the foot 
respecting the L5 dermatome and slight asymmetry of ankle and knee jerks with 
reinforcement required on the left. Pulses were present and straight leg raising test was 
limited to 40°.  
An MRI spinal cord showed multiple lumbosacral disc bulges, most marked at L2/3, 
superimposed on constitutional narrowing of the lumbar vertebral canal due to ligamentum 
flavum hypertrophy and neurosurgical referral for spinal decompression was made (Figure 
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1a). Visualisation of the stenosed segment during surgery allowed for estimation of the 
relative contribution from the L2/3 disc prolapse and ligamentum flavum hypertrophy as 
30% and 70% respectively. Histological examination confirmed the presence of amyloid 
deposits, immunohistochemistry labelled these as transthyretin (Figure 1b). Six weeks post-
operatively she reported marked improvement in pain, exercise tolerance was greater than 
one mile, continence had improved and the area of decreased sensation was reduced to a 
few cm2 around the dorsum of the left great toe, the rest of the neurological examination 
was normal.  
 
This is the first reported case of mutant ATTR-associated spinal stenosis. Given overlapping 
ages of presentation of these conditions and the suggestion that TTR-amyloid may have a 
predilection for early deposition in connective tissue we suggest histological examination for 
amyloid should be considered after spinal decompression when this is caused by 
predominant ligamenum flavum hypertrophy and TTR gene analysis if this is positive. New 
therapeutic strategies in ATTR are emerging so early diagnosis may allow the individual to 
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Figure 1a MRI lumbosacral spine. Sagittal T1 reveal moderate background degenerative disc bulges 
at L2/3, L4/5 and L5/S1 superimposed on constitutional narrowing of thelumbar canal (A) , in 
combination with ligamentum flavum thickening causing moderate stenosis of the vertebral canal.  
 
Figure 1b: Ligamentum flavum histology.  A formalin-fixed, paraffin-embedded section from the 
ligamentum flavum biopsy (L2/3 level) shows one of the fragments of the ligament rich in elastic 
fibres (arrow) containing several amorphous eosinophilic proteinaceous deposits (stars) (A). These 
deposits stain strongly with the Congo Red dye (arrow) (B) and are seen to extend in to the 
cartilaginous intervertebral disc (arrow) that shows severe degenerative changes (C). The Congo 
Red-positive deposits show characteristic apple-green birefringence when visualised under polarised 
light confirming their amyloid nature (D).The deposits stain strongly with TTR-specific 
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